192 related articles for article (PubMed ID: 37089387)
1. Exploration of clinicopathological features of rearranged renal cell carcinoma and TFE3, TFEB, and ALK staining performance in renal entities.
Liu Y; Li X; Fan Y; Xu H; Gu Y; Dong L; Zhou L; Yang X; Wang C
Heliyon; 2023 Apr; 9(4):e15159. PubMed ID: 37089387
[TBL] [Abstract][Full Text] [Related]
2. TFEB Rearranged Renal Cell Carcinoma: Pathological and Molecular Characterization of 10 Cases, with Novel Clinical Implications: A Single Center 10-Year Experience.
Wang AX; Tian T; Liu LB; Yang F; He HY; Zhou LQ
Biomedicines; 2023 Jan; 11(2):. PubMed ID: 36830782
[TBL] [Abstract][Full Text] [Related]
3. Translocation Renal Cell Carcinoma: An Update on Clinicopathological and Molecular Features.
Inamura K
Cancers (Basel); 2017 Aug; 9(9):. PubMed ID: 28850056
[TBL] [Abstract][Full Text] [Related]
4. Translocation carcinomas of the kidney.
Argani P
Genes Chromosomes Cancer; 2022 May; 61(5):219-227. PubMed ID: 34704642
[TBL] [Abstract][Full Text] [Related]
5. TFE3 and TFEB-rearranged renal cell carcinomas: an immunohistochemical panel to differentiate from common renal cell neoplasms.
Caliò A; Marletta S; Brunelli M; Pedron S; Portillo SC; Segala D; Bariani E; Gobbo S; Netto G; Martignoni G
Virchows Arch; 2022 Dec; 481(6):877-891. PubMed ID: 35980471
[TBL] [Abstract][Full Text] [Related]
6. ALK rearrangement in TFE3-positive renal cell carcinoma: Alternative diagnostic option to exclude Xp11.2 translocation carcinoma.
Zhu Y; Liu N; Guo W; Pu X; Guo H; Gan W; Li D
Pathol Res Pract; 2020 Dec; 216(12):153286. PubMed ID: 33197836
[TBL] [Abstract][Full Text] [Related]
7. TFE3 gene rearrangement and protein expression contribute to a poor prognosis of renal cell carcinoma.
Lin J; Tang Z; Zhang C; Dong W; Liu Y; Huang H; Liu H; Huang J; Lin T; Chen X
Heliyon; 2023 May; 9(5):e16076. PubMed ID: 37215783
[TBL] [Abstract][Full Text] [Related]
8. [Clinicopatholigic features of renal cell carcinoma associated with chromosome X inversion harboring gene fusions involving TFE3].
Zhao YN; Wang XT; Xia QY; Wang GP; Sun SY; Zhao LF; Zhou XJ; Rao Q
Zhonghua Bing Li Xue Za Zhi; 2018 Aug; 47(8):574-579. PubMed ID: 30107660
[No Abstract] [Full Text] [Related]
9. ALK-rearranged renal cell carcinoma: a multi-institutional study of nine cases with expanding the morphologic and molecular genetic spectrum.
Zhao M; Yin X; Yang X; Gan H; Chen N; Duan G; Bai Y; Teng X; Xu J; Fang R; Wang S; Zhong S; Wang X; Teng L
Mod Pathol; 2024 Jun; ():100536. PubMed ID: 38852815
[TBL] [Abstract][Full Text] [Related]
10. Genetic analysis and clinicopathological features of ALK-rearranged renal cell carcinoma in a large series of resected Chinese renal cell carcinoma patients and literature review.
Yu W; Wang Y; Jiang Y; Zhang W; Li Y
Histopathology; 2017 Jul; 71(1):53-62. PubMed ID: 28199742
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic approach in TFE3-rearranged renal cell carcinoma: a multi-institutional international survey.
Akgul M; Williamson SR; Ertoy D; Argani P; Gupta S; Caliò A; Reuter V; Tickoo S; Al-Ahmadie HA; Netto GJ; Hes O; Hirsch MS; Delahunt B; Mehra R; Skala S; Osunkoya AO; Harik L; Rao P; Sangoi AR; Nourieh M; Zynger DL; Smith SC; Nazeer T; Gumuskaya B; Kulac I; Khani F; Tretiakova MS; Vakar-Lopez F; Barkan G; Molinié V; Verkarre V; Rao Q; Kis L; Panizo A; Farzaneh T; Magers MJ; Sanfrancesco J; Perrino C; Gondim D; Araneta R; So JS; Ro JY; Wasco M; Hameed O; Lopez-Beltran A; Samaratunga H; Wobker SE; Melamed J; Cheng L; Idrees MT
J Clin Pathol; 2021 May; 74(5):291-299. PubMed ID: 33514585
[TBL] [Abstract][Full Text] [Related]
12. SFPQ/PSF-TFE3 renal cell carcinoma: a clinicopathologic study emphasizing extended morphology and reviewing the differences between SFPQ-TFE3 RCC and the corresponding mesenchymal neoplasm despite an identical gene fusion.
Wang XT; Xia QY; Ni H; Ye SB; Li R; Wang X; Shi SS; Zhou XJ; Rao Q
Hum Pathol; 2017 May; 63():190-200. PubMed ID: 28315422
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic utility of one-stop fusion gene panel to detect TFE3/TFEB gene rearrangement and amplification in renal cell carcinomas.
Harada S; Caliò A; Janowski KM; Morlote D; Rodriguez Pena MD; Canete-Portillo S; Harbi D; DeFrank G; Magi-Galluzzi C; Netto GJ; Martignoni G; Mackinnon AC
Mod Pathol; 2021 Nov; 34(11):2055-2063. PubMed ID: 34148064
[TBL] [Abstract][Full Text] [Related]
14. TFE3-positive renal cell carcinomas are not always Xp11 translocation carcinomas: Report of a case with a TPM3-ALK translocation.
Thorner PS; Shago M; Marrano P; Shaikh F; Somers GR
Pathol Res Pract; 2016 Oct; 212(10):937-942. PubMed ID: 27450657
[TBL] [Abstract][Full Text] [Related]
15. [Clinicopathological characteristics of fumarate hydratase-deficient renal cell carcinoma].
Zhang W; Chu J; Zou YW; Jiang YX; Wei ZM; Zhong DC; Liu Y; Li YJ; Yu WJ
Zhonghua Bing Li Xue Za Zhi; 2019 Feb; 48(2):120-126. PubMed ID: 30695864
[No Abstract] [Full Text] [Related]
16. Genomic alterations and diagnosis of renal cancer.
Zhang X; Bolck HA; Rupp NJ; Moch H
Virchows Arch; 2024 Feb; 484(2):323-337. PubMed ID: 37999735
[TBL] [Abstract][Full Text] [Related]
17. New insights in the new WHO classification of adult renal tumors.
Hes O; Michalová K; Pivovarčíková K
Cesk Patol; 2022; 67(4):187-191. PubMed ID: 36513503
[TBL] [Abstract][Full Text] [Related]
18. Merlin immunohistochemistry is useful in diagnosis of tumours within the spectrum of biphasic hyalinizing psammomatous renal cell carcinoma.
Collins K; Hwang M; Antic T; Paintal A; Argani P; Matoso A; Gopinath A; Baskovich B; Mehra R; Williamson SR; Idrees MT; Barletta JA; Anderson WJ; Hirsch MS; Hornick JL; Acosta AM
Histopathology; 2022 Nov; 81(5):577-586. PubMed ID: 35971742
[TBL] [Abstract][Full Text] [Related]
19. Morphologic and Immunohistochemical Characteristics of Fluorescent In Situ Hybridization Confirmed TFE3-Gene Fusion Associated Renal Cell Carcinoma: A Single Institutional Cohort.
Akgul M; Saeed O; Levy D; Mann SA; Cheng L; Grignon DJ; Eble JN; Idrees MT
Am J Surg Pathol; 2020 Nov; 44(11):1450-1458. PubMed ID: 32701515
[TBL] [Abstract][Full Text] [Related]
20. [Clinicopathological features and prognosis of fumarate hydratase deficient renal cell carcinoma].
Yu YF; He SM; Wu YC; Xiong SW; Shen Q; Li YY; Yang F; He Q; Li XS
Beijing Da Xue Xue Bao Yi Xue Ban; 2021 Aug; 53(4):640-646. PubMed ID: 34393221
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
